XYou may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at email@example.com.
Is hopelessness a critical risk factor for suicidal intent, especially for depressed individuals? The authors of this brief report explore the link between hopelessness and suicidal intent and offer suggestions for future research.
This study compared the prevalence of depression and suicidal behavior along with the use and cost of related treatment in young adults with and without attention-deficit/hyperactivity disorder using commercial claims data.
Suicide rates are an indicator used to monitor mental health in the UN's Sustainable Development Goals. This study analyzed WHO and UN data from 62 countries to see if suicide rates and happiness are correlated. Read it to see the surprising results.
When pregnant patients with a history of depression ask you about eating fish or using an omega-3 supplement, what do you tell them? Learn about research in the peripartum period in this journal CME activity.
This study evaluated the efficacy and tolerability of escitalopram in adolescents with generalized anxiety disorder as well as the impact of variants in genes and CYP2C19 phenotypes on response and of CYP2C19 phenotypes on escitalopram pharmacokinetics.
The effects of antidepressants and treatment duration on the progression to dementia are currently unclear. This case-control study analyzed the effects of several antidepressants with different treatment durations on the risk of developing dementia.
An antidepressant medication switch often follows a failed initial trial with SSRIs. This study sought to determine the probability and timing of both response and remission and the optimal duration of several second-step antidepressant treatments.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”